Biogen(US:BIIB)2023-11-08 13:13Financial Performance - Total revenue increased by 1% to $2.53 billion, or 3% at constant currency, compared to Q3 2022[35,44] - GAAP diluted EPS was $(0.47), a decrease of 106% compared to Q3 2022[35] - Non-GAAP diluted EPS was $4.36, a decrease of 9% compared to Q3 2022[35] - Multiple sclerosis product revenue decreased by 14% to $1.159 billion, or 12% at constant currency[44] - Spinal muscular atrophy revenue increased by 4% to $448 million, or 7% at constant currency[44] - Biosimilars revenue increased by 4% to $194 million, or 7% at constant currency[44] - Contract manufacturing, royalty and other revenue increased significantly by 135% to $304 million[44] Product and Pipeline Updates - SKYCLARYS U.S. launch is underway, with approximately 1,180 total start forms to date and estimated sales of $43 million with approximately 860 total patients[17] - LEQEMBI subcutaneous formulation BLA planned submission by the end of Q1 2024[30] Strategic Initiatives - The "Fit for Growth" program aims for approximately $700 million in net savings by 2025[55]